Translational Solutions
Harnessing fresh human samples to provide unrivalled translational insights
Generate Clinically Relevant Data
Synexa’s translational service is dedicated to understanding candidate therapeutics and biomarker data in order to generate clinically relevant data, using fresh human samples from both healthy and diseased populations.
Utilising a broad range of technologies, Synexa assesses candidate drugs in clinically relevant samples from a broad range of therapeutic indications, delivering critical insights including the safety profile, efficacy and mechanism of action, providing the assurance needed to confidently progress into clinical trials.
Unlock Key Therapeutic Insights:
- Early Efficacy & Safety Insights: Assess drug efficacy, safety, and pharmacodynamics before clinical entry
- Indication Prioritisation: Evaluate therapeutic potential across multiple diseases to refine focus
- Competitive Benchmarking: Compare against drug leads against marketed competitors
- Rapid Iteration: Accelerate development with efficient testing cycles
Reduce Your Development Risk:
Real-World Insights
We source disease-relevant patient samples, providing a more accurate reflection of human biology as well as improving future trial efficiency and patient safety.
Reduced Development Risk/Costs
Early identification of promising candidates minimises the likelihood of late-stage failures and enhances confidence in moving candidates to clinical trials.
Improved Predictive Power
Improved understanding of drug mechanisms and biomarker profiles in human disease contexts for patient stratification.
Regulatory Advantages
Our translational solutions complement animal models, aligning with industry trends toward human-centric research.
Diverse Sample Matrices
Our clinical network can provide diverse, disease-relevant samples across a range of matrices, including blood, tissues, BALF and CSF.
Advanced Technologies
We harness the latest analytical technologies including Olink, Meso Scale Discovery (MSD), dPCR, and flow cytometry.
End-to-end Support
Our teams provide end-to-end support, from study design to sample processing and integrated data analysis.
- Consultation and protocol design
Specialised team with a deep understanding of disease mechanisms and treatment landscape - Experimental design
Flexibility and customisation, each solution is tailored to meet the unique needs of a therapeutic candidate - Ethical approval and sample collection
We collaborate with a large network of clinical sites to obtain ethically sourced, fresh patient samples from diverse populations with full clinical data collection - Data generation and analysis
Integrated with our advanced analytical platforms, we generate robust, actionable datasets that mirror real-life patient responses - Decision making and integration with clinical development
Rapid data processing and interim reports to inform decision making and potential trial adaptations, incorporating biomarker signatures of response
Ethical Patient Sample Collection
Meet a clinician from our extensive clinical network.
We collaborate with a diverse range of clinicians within our extensive clinical network to ethically source a broad range of samples and matrices that can be utilised for translational studies.
Learn why Professor Helmuth Reuter, Director of the Winelands Medical Research Centre and a renowned key opinion leader, partners with Synexa to help advance translational research and drug development.
See our ethical patient sampling process in action.
At Synexa, ethical integrity is the foundation of every clinical study we support. We approach informed consent with the care, clarity, and rigour required for international and multisite trials.
All patients provide their informed consent before participating in any study, allowing for multiple opportunities to ask questions and learn more about the clinical trial taking place. We follow stringent national and international guidelines to ensure the ethical integrity of each of our studies.
FAQ
What is translational science in the context of biomarker research?
In biomarker research, translational science refers to the process of turning laboratory-based insights into clinically meaningful outcomes. At Synexa, this involves designing and deploying fit-for-purpose assays that link molecular signatures with disease mechanisms, patient stratification strategies, and therapeutic responses – particularly in immunology and rare diseases.
How does Synexa's translational service work?
Synexa’s translational approach begins with understanding the clinical question and therapeutic context. From there, we design mechanistically relevant biomarker strategies, selecting or developing fit-for-purpose assays that generate data aligned with trial objectives. Using a range of advanced platforms, including flow cytometry, MSD, and genomics, we analyse biological samples to identify meaningful patterns. The resulting data are interpreted by our scientific teams to inform patient stratification, target engagement, and drug mechanism-of-action insights, ultimately bridging the gap between discovery science and clinical outcomes.
Where do the samples Synexa utilises for translational studies come from?
Synexa Life Sciences sources ethically obtained, fresh human samples through a trusted global clinical network. These samples come from both healthy individuals and patients across various disease indications and at different stages of disease progression. Each sample is accompanied by relevant clinical data and is selected to support biomarker discovery, target engagement, and proof-of-biology studies. Our access to diverse patient populations and sample matrices enables precise profiling and translational insights. With world-class clinical experts and key opinion leaders guiding our approach, Synexa ensures scientific certainty and logistical excellence in every study.
What platforms and technologies are used in Synexa’s translational biomarker services?
Synexa leverages a broad range of platforms including flow cytometry, MSD, qPCR, and high-resolution mass spectrometry to generate mechanistically relevant biomarker data. All assays are developed with clinical context in mind, ensuring alignment with regulatory and therapeutic goals.
How does Synexa support patient stratification in clinical trials?
Synexa applies deep immunophenotyping, multi-omic profiling, and customised biomarker panels to identify sub-populations most likely to respond to therapy. This enables data-driven patient stratification strategies that enhance trial success and accelerate precision medicine approaches.
Improving the quality of human health
Contact us
Discuss biomarker and bioanalytical solutions to accelerate your therapeutic pipeline
